Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Market Conflict Next Week: What To Watch

2018-02-19 seekingalpha
After a wild and volatile 2 weeks, what to think about for the short trading week to come. (436-2)

TGTX / TG Therapeutics, Inc. / BRIDGER MANAGEMENT, LLC - 13G/A (Passive Investment)

2018-02-15 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)* TG Therapeutics, Inc. (Name of Issuer)   Common Stock, $0.001 Par Value (Title of Class of Securities)   88322Q108 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   o Rule 13d-1(b) x Rule 13d-1(c) o Rule 13d-1(d

TGTX / TG Therapeutics, Inc. / BRIDGER MANAGEMENT, LLC - 13G/A (Passive Investment)

2018-02-15 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)* TG Therapeutics, Inc. (Name of Issuer)   Common Stock, $0.001 Par Value (Title of Class of Securities)   88322Q108 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   o Rule 13d-1(b) x Rule 13d-1(c) o Rule 13d-1(d

TGTX / TG Therapeutics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 4 TG THERAPEUTICS INC COMMON STOCK Cusip #88322Q108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #88322Q108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 4,951,213 Item 8: 0 Item 9: 4,951,213 Item 11: 7.007% Item 12: HC Cusip #88322Q108 Item 1: Reporting Person - Abigail P.

TGTX / TG Therapeutics, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 4 TG THERAPEUTICS INC COMMON STOCK Cusip #88322Q108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #88322Q108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 4,951,213 Item 8: 0 Item 9: 4,951,213 Item 11: 7.007% Item 12: HC Cusip #88322Q108 Item 1: Reporting Person - Abigail P.

TG Therapeutics: Further Appreciation In 2018 Likely

2018-02-06 seekingalpha
The in-licensing of Jiangsu Hengrui Medicine Co.'s BTK inhibitor program was a masterful move that could pay dividends down the road for shareholders. (18-0)

Biotech Forum Daily Digest For February 3rd

2018-02-04 seekingalpha
The biotech sector is plummeting with the rest of the market this week trapped within a 'hiccup' that hits equities from time to time. (195-2)

Your Daily Pharma Scoop: MediciNova's MN-166, Amgen's Results, TG Therapeutics Data

2018-02-03 seekingalpha
MediciNova reported presentation of additional positive clinical data from the SPRINT-MS Phase 2b Trial of MN-166. (57-1)

TGTX / TG Therapeutics, Inc. V020218_8K (Current Report)

2018-02-02 sec.gov
Blueprint       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________   FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934     Date of report (Date of earliest event reported): February 2, 2018       TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)         Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identific

Biotech Forum Daily Digest For January 29th

2018-01-29 seekingalpha
Biotech just had one of best weeks in recent memory and we have another acquisition this morning to report. (326-1)

2 Small Biotechs With Substantial Upside Potential

2018-01-26 seekingalpha
The biotech sector is perking up this week on the back of two big acquisitions and improved sentiment on the space. (26-1)

Biotech Forum Daily Digest For Jan. 8th

2018-01-08 seekingalpha
The biotech sector had a solid start to 2018, as did the overall market. The sector is selling off to start this week, however. (356-3)

TGTX / TG Therapeutics, Inc. 8-K (Current Report)

2018-01-08 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________ FORM 8-K _____________   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): January 8, 2018   TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation) 001-32639 (Commission File Number)   36-3898269 (IRS Employer Identification No.

BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies

2018-01-08 reuters
* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES (18-0)


TGTX : TG Therapeutics Stock Analysis and Research Report

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, TG Therapeutics is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors, BET (Bromodomain an...

Click for full article
CUSIP: 88322Q108